Delcath Systems, Inc.

Delcath Systems, Inc. is a commercial-stage interventional oncology company specializing in minimally invasive treatments for primary and metastatic liver cancers. The company's flagship product, HEPZATO KIT™ (melphalan) for Injection/Hepatic Delivery System (HDS), received FDA approval for treating adult patients with metastatic uveal melanoma. In Europe, the equivalent product is marketed as CHEMOSAT® Hepatic Delivery System for melphalan percutaneous hepatic perfusion (PHP). The company addresses a significant clinical gap: liver cancers affect approximately 1.2 million people globally annually, yet treatment options remain limited. Delcath's interventional oncology platform delivers targeted chemotherapy directly to hepatic tumors via percutaneous hepatic perfusion, enabling concentrated drug delivery while minimizing systemic exposure. The company is positioned as a leader in safe, effective, and targeted treatments for patients with liver metastases, including secondary cancers from uveal melanoma and other primary hepatic malignancies. HEPZATO KIT represents a recent FDA-approved advancement in the interventional oncology space, expanding therapeutic options for previously underserved patient populations.